Corcept Therapeutics CORT Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's retained earnings?
- Corcept Therapeutics (CORT) reported retained earnings of $611.63M in Q1 2026.
- How has Corcept Therapeutics's retained earnings changed year-over-year?
- Corcept Therapeutics's retained earnings increased by 8.4% year-over-year, from $564.28M to $611.63M.
- What is the long-term trend for Corcept Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Corcept Therapeutics's retained earnings has grown at a 50.8% compound annual growth rate (CAGR), from $82.46M to $643.39M.
- What does retained earnings mean?
- The total profit the company has kept and reinvested since it started.
- How do you interpret retained earnings?
- A steady increase indicates consistent profitability and successful reinvestment of earnings into the business.
- How does retained earnings compare across companies?
- A key indicator of long-term financial health and maturity for profitable firms.